NCT01523808View on ClinicalTrials.gov

Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase)in Patients With Pancreatic Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions

Pancreatic Cancer

Interventions

DRUG

GRASPA

Each patient will receive one administration of GRASPA . A stepwise increase of 4 single doses of GRASPA will be administered to cohorts of 3 patients per dose